The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

A mix of tolerable benefit cuts and realistic revenue increases would make everyone better off In early January, Stephen Goss, Social Security's chief actuary released estimates of a comprehensive ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...